NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $8.31 -0.35 (-4.04 %) (As of 12/16/2018 04:00 PM ET)Previous Close$8.31Today's Range$8.18 - $8.6452-Week Range$3.61 - $27.06Volume65,651 shsAverage Volume121,641 shsMarket Capitalization$132.20 millionP/E Ratio-8.48Dividend YieldN/ABeta2.88 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd. Receive GLMD News and Ratings via Email Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLMD Previous Symbol CUSIPN/A Webwww.galmedpharma.com Phone972-3693-8448 Debt Debt-to-Equity RatioN/A Current Ratio43.47 Quick Ratio43.47 Price-To-Earnings Trailing P/E Ratio-8.48 Forward P/E Ratio-17.31 P/E GrowthN/A Sales & Book Value Annual Sales$1.09 million Price / Sales121.30 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book6.70 Profitability EPS (Most Recent Fiscal Year)($0.98) Net Income$-12,290,000.00 Net Margins-423.62% Return on Equity-18.55% Return on Assets-17.52% Miscellaneous Employees17 Outstanding Shares15,910,000Market Cap$132.20 million OptionableOptionable Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions What is Galmed Pharmaceuticals' stock symbol? Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD." How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) posted its earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.09. The biopharmaceutical company earned $1.50 million during the quarter, compared to analysts' expectations of $0.30 million. Galmed Pharmaceuticals had a negative net margin of 423.62% and a negative return on equity of 18.55%. View Galmed Pharmaceuticals' Earnings History. When is Galmed Pharmaceuticals' next earnings date? Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Galmed Pharmaceuticals. What price target have analysts set for GLMD? 7 brokers have issued 1 year price targets for Galmed Pharmaceuticals' stock. Their predictions range from $20.00 to $59.00. On average, they expect Galmed Pharmaceuticals' share price to reach $37.6250 in the next year. This suggests a possible upside of 352.8% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals. What is the consensus analysts' recommendation for Galmed Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals. Has Galmed Pharmaceuticals been receiving favorable news coverage? Press coverage about GLMD stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Galmed Pharmaceuticals earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. Who are some of Galmed Pharmaceuticals' key competitors? Some companies that are related to Galmed Pharmaceuticals include Ra Pharmaceuticals (RARX), NuCana (NCNA), CymaBay Therapeutics (CBAY), Basilea Pharmaceutica (BPMUF), Aurinia Pharmaceuticals (AUPH), ChemoCentryx (CCXI), Flexion Therapeutics (FLXN), Theratechnologies (THERF), Innate Pharma (IPHYF), Prothena (PRTA), Epizyme (EPZM), Corium International (CORI), Arvinas (ARVN), Beyondspring (BYSI) and Rigel Pharmaceuticals (RIGL). Who are Galmed Pharmaceuticals' key executives? Galmed Pharmaceuticals' management team includes the folowing people: Mr. Yohai Stenzler, CFO & Controller (Age 35)Mr. Guy Nehemya, VP of Operations (Age 33)Dr. Liat Hayardeny, Chief Scientific Officer (Age 51)Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 35)Dr. Tali Gorfine, Chief Medical Officer (Age 48) Who are Galmed Pharmaceuticals' major shareholders? Galmed Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (5.35%), Ibex Investors LLC (2.63%), Baker BROS. Advisors LP (2.04%), Morgan Stanley (0.83%), Point72 Asset Management L.P. (0.72%) and P.A.W. Capital Corp (0.57%). Which major investors are selling Galmed Pharmaceuticals stock? GLMD stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Baker BROS. Advisors LP, Morgan Stanley and P.A.W. Capital Corp. Which major investors are buying Galmed Pharmaceuticals stock? GLMD stock was acquired by a variety of institutional investors in the last quarter, including Ibex Investors LLC, Vivo Capital LLC, ARK Investment Management LLC, Wells Fargo & Company MN and Trellus Management Company LLC. How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Galmed Pharmaceuticals' stock price today? One share of GLMD stock can currently be purchased for approximately $8.31. How big of a company is Galmed Pharmaceuticals? Galmed Pharmaceuticals has a market capitalization of $132.20 million and generates $1.09 million in revenue each year. The biopharmaceutical company earns $-12,290,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe. What is Galmed Pharmaceuticals' official website? The official website for Galmed Pharmaceuticals is http://www.galmedpharma.com. How can I contact Galmed Pharmaceuticals? Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448. MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 320 (Vote Outperform)Underperform Votes: 150 (Vote Underperform)Total Votes: 470MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: Do stock splits help investors?